EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)

Efficacy and Safety of Ferric Citrate on Hyperphosphatemia among Chinese Patients with Chronic Kidney Disease Undergoing Hemodialysis: A Phase III Multicenter Randomized Open-Label Active-Drug-Controlled Study

Yong Wang, Xiangmei Chen, Hanyu Zhu, Zhiyong Guo, Yibin Yang, Ping Luo, Yani He, Yan Xu, Daxi Ji, Xinlu Gao, Xiuli Sun, Changying Xing und 12 weitere

American Journal of Nephrology · 2023

DOI: 10.1159/000534484 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Nephrology, 2023. Verfasst von Yong Wang und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, First Medical Center of Chinese PLA General Hospital, Nephrology Institute of the Chinese People's Liberation Army, State K…. Hauptthemen laut MEDLINE: Hyperphosphatemia, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Hyperphosphatemia in chronic kidney disease (CKD) patients is positively associated with mortality. Ferric citrate is a potent phosphorus binder that lowers serum phosphorus level and improves iron metabolism. We compared its efficacy and safety with active drugs in Chinese CKD patients with hemodialysis.

Methods

Chinese patients undergoing hemodialysis were randomized into two treatment groups in a 1:1 ratio, receiving either ferric citrate or sevelamer carbonate, respectively, for 12 weeks. Serum phosphorus levels, calcium concentration, and iron metabolism parameters were evaluated every 2 weeks. Frequency and severity of adverse events were recorded.

Results

217 (90.4%) patients completed the study with balanced demographic and baseline characteristics between two groups. Ferric citrate decreased the serum phosphorus level to 0.59 ± 0.54 mmol/L, comparable to 0.56 ± 0.62 mmol/L by sevelamer carbonate. There was no significant difference between two groups (p > 0.05) in the proportion of patients with serum phosphorus levels reaching the target range, the response rate to the study drug, and the changes of corrected serum calcium concentrations, and intact-PTH levels at the end of treatment. The change of iron metabolism indicators in the ferric citrate group was significantly higher than those in the sevelamer carbonate group. There are 47 (40.5%) patients in the ferric citrate group, and 26 (21.3%) patients in the sevelamer carbonate group experienced drug-related treatment emergent adverse events (TEAEs); most were mild and tolerable. Common drug-related TEAEs were gastrointestinal disorders, including diarrhea (12.9 vs. 2.5%), fecal discoloration (14.7 vs. 0%), and constipation (1.7 vs. 7.4%) in ferric citrate and sevelamer carbonate group.

Conclusion

Ferric citrate capsules have good efficacy and safety in the control of hyperphosphatemia in adult patients with CKD undergoing hemodialysis. Efficacy is not inferior to sevelamer carbonate. The TEAEs were mostly mild and tolerated by the patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperphosphatemiaRenal Insufficiency, ChronicAdultHumansSevelamerCalciumChelating AgentsRenal DialysisFerric CompoundsPhosphorusIronChina

Substanzen

Sevelamerferric citrateCalciumChelating AgentsFerric CompoundsPhosphorusIron

Autor:innen und Institutionen

  • Department of Nephrology, First Medical Center of Chinese PLA General Hospital, Nephrology Institute of the Chinese People's Liberation Army, State Key Laboratory of Kidney Diseases, National Clinical Research Center fo…
  • Department of Nephrology, Changhai Hospital of Shanghai, Naval Medical University, Shanghai, China.
  • Department of Nephrology, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
  • Department of Nephrology, The Second Hospital of Jilin University, Changchun, China.
  • Department of Nephrology, Daping Hospital, Army Medical University, Chongqing, China.
  • Department of Nephrology, The Affiliated Hospital of Qingdao University, Qingdao, China.

Zitieren

APA

Wang, Y., Chen, X., Zhu, H., Guo, Z., Yang, Y., Luo, P., He, Y., Xu, Y., Ji, D., Gao, X., Sun, X., Xing, C., Wang, Y., Wang, X., Zhao, S., Guan, Y., Lin, H., Zhong, A., Shui, H., …, & Zhang, L. (2023). Efficacy and Safety of Ferric Citrate on Hyperphosphatemia among Chinese Patients with Chronic Kidney Disease Undergoing Hemodialysis: A Phase III Multicenter Randomized Open-Label Active-Drug-Controlled Study. American Journal of Nephrology. https://doi.org/10.1159/000534484

Vancouver

Wang Y, Chen X, Zhu H, Guo Z, Yang Y, Luo P, et al. Efficacy and Safety of Ferric Citrate on Hyperphosphatemia among Chinese Patients with Chronic Kidney Disease Undergoing Hemodialysis: A Phase III Multicenter Randomized Open-Label Active-Drug-Controlled Study. American Journal of Nephrology. 2023. doi:10.1159/000534484

BibTeX
@article{Wang2023,
  author = {Wang, Yong and Chen, Xiangmei and Zhu, Hanyu and Guo, Zhiyong and Yang, Yibin and Luo, Ping and He, Yani and Xu, Yan and Ji, Daxi and Gao, Xinlu and Sun, Xiuli and Xing, Changying and Wang, Yu and Wang, Xiaohui and Zhao, Shuping and Guan, Yan and Lin, Hongli and Zhong, Aimin and Shui, Hua and Shao, Fengmin and Lv, Lu and Yan, Yuehong and Sun, Xiaokun and Zhang, Lei},
  title = {Efficacy and Safety of Ferric Citrate on Hyperphosphatemia among Chinese Patients with Chronic Kidney Disease Undergoing Hemodialysis: A Phase III Multicenter Randomized Open-Label Active-Drug-Controlled Study},
  journal = {American Journal of Nephrology},
  year = {2023},
  doi = {10.1159/000534484}
}
Kostenlos starten →